New insights into how DMTs may affect COVID-19 outcomes

In a COVID-19 session at MSVirtual2020, specialists reported data – sometimes conflicting – from several studies investigating links between disease modifying therapies (DMTs) and COVID-19 outcomes.

Dr Steve Simpson-Yap from the University of Melbourne, Australia, presented the first results from the MS Global Data Sharing Initiative, with data on 1,540 MS patients, including 476 with suspected COVID-19 and 776 with confirmed COVID-19.